Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese male or female participants between the ages of 20 and 85 years, inclusive, at randomization.~* Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.~* Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.~* Capable of giving personal signed informed consent.~Exclusion Criteria:~* Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.~* Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).~* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).~* Receipt of medications intended to prevent COVID-19.~* Previous confirmed diagnosis of COVID-19.~* Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.~* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.~* Women who are pregnant or breastfeeding.~* Previous vaccination with any coronavirus vaccine.~* Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.~* Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.~* Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.~* Previous participation in other studies involving study intervention containing lipid nanoparticles.~* Subset only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.~* Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- BNT162b2 (Type: EXPERIMENTAL): BNT162b2 (intramuscular injection)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo (intramuscular injection)

Based on this trial design, predict the completion outcome and termination type (if applicable).